Cargando…
Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells?
BACKGROUND: Extranodal NK/T-cell lymphoma, nasal type (ENKL) is a distinct clinicopathological entity and EBV-associated disease that is highly aggressive. Many patients had failed to respond to conventional chemotherapy or relapsed after treatment. Multi-drug resistance is a major cause that leads...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167813/ https://www.ncbi.nlm.nih.gov/pubmed/30302057 http://dx.doi.org/10.1186/s12935-018-0644-6 |
_version_ | 1783360264041660416 |
---|---|
author | Zhang, Xudong Fu, Xiaorui Dong, Meng Yang, Zhenzhen Wu, Shaoxuan Ma, Mijing Li, Zhaoming Wang, Xinhua Li, Ling Li, Xin Sun, Zhenchang Chang, Yu Nan, Feifei Yan, Jiaqin Mao, Yun Zhang, Mingzhi Chen, Qingjiang |
author_facet | Zhang, Xudong Fu, Xiaorui Dong, Meng Yang, Zhenzhen Wu, Shaoxuan Ma, Mijing Li, Zhaoming Wang, Xinhua Li, Ling Li, Xin Sun, Zhenchang Chang, Yu Nan, Feifei Yan, Jiaqin Mao, Yun Zhang, Mingzhi Chen, Qingjiang |
author_sort | Zhang, Xudong |
collection | PubMed |
description | BACKGROUND: Extranodal NK/T-cell lymphoma, nasal type (ENKL) is a distinct clinicopathological entity and EBV-associated disease that is highly aggressive. Many patients had failed to respond to conventional chemotherapy or relapsed after treatment. Multi-drug resistance is a major cause that leads to these desperate failures. However, the specific mechanism of drug resistance is still unclear. METHODS: In the previous study, we firstly developed a doxorubicin-resistant ENKL cell line known as SNK-6/ADM, and then a small quantity of side population (SP) cells were derived from SNK-6/ADM and named SNK-6/ADM-SP. In order to explore the biological characteristics and mechanism of drug-resistance of these cells, SNK-6, SNK-6/ADM and SNK-6/ADM-SP cells were utilized to evaluate potentially differences of chemotherapy resistance index (RI), morphology, proliferation, cell cycles, expression of ATP-binding cassette (ABC) transporters (ABCG1, ABCG2 and ABCC4) and surface markers, cytokine sensitivity, and situation of EBV infection. RESULTS: We identified SNK-6/ADM-SP is a specific multidrug resistant cell population with a higher level of RI than SNK-6/ADM. Relevant evaluations showed that SNK-6/ADM-SP presented a series of conserved biological behaviors including relatively poor proliferation ability, high expression of ABCG2, weak sensitivity to IL-15 which could stimulate normal ENKL cells’ proliferation and differentiation, and EBV inhibition with low level of EBV-DNA replication and EBV-antigen expression. CONCLUSIONS: This discovered cellular heterogeneity of ENKL could provide a new perspective to better understand the mechanisms of drug resistance and overcome elusive response to chemotherapy of ENKL. |
format | Online Article Text |
id | pubmed-6167813 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-61678132018-10-09 Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells? Zhang, Xudong Fu, Xiaorui Dong, Meng Yang, Zhenzhen Wu, Shaoxuan Ma, Mijing Li, Zhaoming Wang, Xinhua Li, Ling Li, Xin Sun, Zhenchang Chang, Yu Nan, Feifei Yan, Jiaqin Mao, Yun Zhang, Mingzhi Chen, Qingjiang Cancer Cell Int Primary Research BACKGROUND: Extranodal NK/T-cell lymphoma, nasal type (ENKL) is a distinct clinicopathological entity and EBV-associated disease that is highly aggressive. Many patients had failed to respond to conventional chemotherapy or relapsed after treatment. Multi-drug resistance is a major cause that leads to these desperate failures. However, the specific mechanism of drug resistance is still unclear. METHODS: In the previous study, we firstly developed a doxorubicin-resistant ENKL cell line known as SNK-6/ADM, and then a small quantity of side population (SP) cells were derived from SNK-6/ADM and named SNK-6/ADM-SP. In order to explore the biological characteristics and mechanism of drug-resistance of these cells, SNK-6, SNK-6/ADM and SNK-6/ADM-SP cells were utilized to evaluate potentially differences of chemotherapy resistance index (RI), morphology, proliferation, cell cycles, expression of ATP-binding cassette (ABC) transporters (ABCG1, ABCG2 and ABCC4) and surface markers, cytokine sensitivity, and situation of EBV infection. RESULTS: We identified SNK-6/ADM-SP is a specific multidrug resistant cell population with a higher level of RI than SNK-6/ADM. Relevant evaluations showed that SNK-6/ADM-SP presented a series of conserved biological behaviors including relatively poor proliferation ability, high expression of ABCG2, weak sensitivity to IL-15 which could stimulate normal ENKL cells’ proliferation and differentiation, and EBV inhibition with low level of EBV-DNA replication and EBV-antigen expression. CONCLUSIONS: This discovered cellular heterogeneity of ENKL could provide a new perspective to better understand the mechanisms of drug resistance and overcome elusive response to chemotherapy of ENKL. BioMed Central 2018-10-01 /pmc/articles/PMC6167813/ /pubmed/30302057 http://dx.doi.org/10.1186/s12935-018-0644-6 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Primary Research Zhang, Xudong Fu, Xiaorui Dong, Meng Yang, Zhenzhen Wu, Shaoxuan Ma, Mijing Li, Zhaoming Wang, Xinhua Li, Ling Li, Xin Sun, Zhenchang Chang, Yu Nan, Feifei Yan, Jiaqin Mao, Yun Zhang, Mingzhi Chen, Qingjiang Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells? |
title | Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells? |
title_full | Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells? |
title_fullStr | Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells? |
title_full_unstemmed | Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells? |
title_short | Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells? |
title_sort | conserved cell populations in doxorubicin-resistant human nasal natural killer/t cell lymphoma cell line: super multidrug resistant cells? |
topic | Primary Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167813/ https://www.ncbi.nlm.nih.gov/pubmed/30302057 http://dx.doi.org/10.1186/s12935-018-0644-6 |
work_keys_str_mv | AT zhangxudong conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells AT fuxiaorui conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells AT dongmeng conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells AT yangzhenzhen conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells AT wushaoxuan conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells AT mamijing conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells AT lizhaoming conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells AT wangxinhua conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells AT liling conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells AT lixin conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells AT sunzhenchang conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells AT changyu conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells AT nanfeifei conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells AT yanjiaqin conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells AT maoyun conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells AT zhangmingzhi conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells AT chenqingjiang conservedcellpopulationsindoxorubicinresistanthumannasalnaturalkillertcelllymphomacelllinesupermultidrugresistantcells |